Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 醫學院
  3. 臨床醫學研究所
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/41939
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor楊偉勛
dc.contributor.authorJui-Kun Chiangen
dc.contributor.author江瑞坤zh_TW
dc.date.accessioned2021-06-15T00:38:22Z-
dc.date.available2010-12-18
dc.date.copyright2008-12-18
dc.date.issued2008
dc.date.submitted2008-11-06
dc.identifier.citation1.江瑞坤 等:新陳代謝症候群. 基層醫學 2005;20:2-7.
2.Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
3. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-50.
4. Vahratian A. Prevalence of Overweight and Obesity Among Women of Childbearing Age: Results from the 2002 National Survey of Family Growth. Maternal and child health journal 2008.
5. Park HS, Park CY, Oh SW, Yoo HJ. Prevalence of obesity and metabolic syndrome in Korean adults. Obes Rev 2008;9:104-7.
6. Zhang X, Sun Z, Zhang X, et al. Prevalence and associated factors of overweight and obesity in a Chinese rural population. Obesity (Silver Spring, Md 2008;16:168-71.
7. Shiri R, Solovieva S, Husgafvel-Pursiainen K, et al. The association between obesity and the prevalence of low back pain in young adults: the Cardiovascular Risk in Young Finns Study. American journal of epidemiology 2008;167:1110-9.
8. Lee SA, Wen W, Xu WH, et al. Prevalence of obesity and correlations with lifestyle and dietary factors in Chinese men. Obesity (Silver Spring, Md 2008;16:1440-7.
9. Lijnen HR, Van Hoef B, Lu HR, Gallacher DJ. Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity. Thrombosis and haemostasis 2008;100:338-42.
10. Limosin F, Gasquet I, Leguay D, Azorin JM, Rouillon F. Body mass index and prevalence of obesity in a French cohort of patients with schizophrenia. Acta psychiatrica Scandinavica 2008;118:19-25.
11. Sen Y, Kandemir N, Alikasifoglu A, Gonc N, Ozon A. Prevalence and risk factors of metabolic syndrome in obese children and adolescents: the role of the severity of obesity. European journal of pediatrics 2008.
12. Nyholm M, Gullberg B, Rastam L, Lindblad U. What is the accurate prevalence of obesity in Sweden in the 21st century? Methodological experiences from the skaraborg project. Obesity (Silver Spring, Md 2008;16:896-8.
13. Pi-Sunyer FX. Obesity: criteria and classification. The Proceedings of the Nutrition Society 2000;59:505-9.
14. Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria and classification of obesity in Japan and Asia-Oceania. Asia Pacific journal of clinical nutrition 2002;11 Suppl 8:S732-S7.
15. Hwang LC, Bai CH, Chen CJ. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc 2006;105:626-35.
16. Nestel P, Lyu R, Low LP, et al. Metabolic syndrome: recent prevalence in East and Southeast Asian populations. Asia Pac J Clin Nutr 2007;16:362-7.
17. West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994. Am J Kidney Dis 2008;51:741-7.
18. Segrest JP, Jackson RL, Morrisett JD, Gotto AM, Jr. A molecular theory of lipid-protein interactions in the plasma lipoproteins. FEBS letters 1974;38:247-58.
19. Cassader M, Gambino R, Musso G, et al. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids 2001;36:1117-24.
20. Lin J, Peng F, Zeng K, Wu K, Kang Q. [The relationship between insulin resistance and postprandial abnormal serum triglyceride metabolism in essential hypertension]. Zhonghua yi xue za zhi 2002;82:1521-4.
21. Zieden B, Molgaard J, Olsson AG. Low-density lipoprotein oxidation and coronary atherosclerosis. Lancet 1992;340:727-8.
22. Bouhours-Nouet N, Dufresne S, de Casson FB, et al. High birth weight and early postnatal weight gain protect obese children and adolescents from truncal adiposity and insulin resistance: metabolically healthy but obese subjects? Diabetes Care 2008;31:1031-6.
23. Kumar S, O'Rahilly S. Insulin Resistance: insulin action and its disturbances in disease. West Sussex: John Wiley & Sons, Ltd; 2005.
24. Novak S, Stapleton LM, Litaker JR, Lawson KA. A confirmatory factor analysis evaluation of the coronary heart disease risk factors of metabolic syndrome with emphasis on the insulin resistance factor. Diabetes Obes Metab 2003;5:388-96.
25. Sourij H, Schmoelzer I, Dittrich P, Paulweber B, Iglseder B, Wascher TC. Insulin resistance as a risk factor for carotid atherosclerosis: a comparison of the Homeostasis Model Assessment and the short insulin tolerance test. Stroke 2008;39:1349-51.
26. Sung KC, Ryu SH. Insulin resistance, body mass index, waist circumference are independent risk factor for high blood pressure. Clin Exp Hypertens 2004;26:547-56.
27. Chen W, Srinivasan SR, Elkasabany A, Berenson GS. The association of cardiovascular risk factor clustering related to insulin resistance syndrome (Syndrome X) between young parents and their offspring: the Bogalusa Heart Study. Atherosclerosis 1999;145:197-205.
28. Dimartino-Nardi J. Insulin resistance in prepubertal african-american and Hispanic girls with premature adrenarche: a risk factor for polycystic ovary syndrome. Trends Endocrinol Metab 1998;9:78-82.
29. Rubin DA, McMurray RG, Harrell JS, Hackney AC, Thorpe DE, Haqq AM. The association between insulin resistance and cytokines in adolescents: the role of weight status and exercise. Metabolism 2008;57:683-90.
30. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. J Appl Physiol 2005;99:2008-19.
31. Caballero AE, Bousquet-Santos K, Robles-Osorio L, et al. Overweight Latino children and adolescents have marked endothelial dysfunction and subclinical vascular inflammation in association with excess body fat and insulin resistance. Diabetes Care 2008;31:576-82.
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
33. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95.
34. Turner RC, Holman RR, Matthews D, Hockaday TD, Peto J. Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism 1979;28:1086-96.
35. Rudenski AS, Matthews DR, Levy JC, Turner RC. Understanding 'insulin resistance': both glucose resistance and insulin resistance are required to model human diabetes. Metabolism 1991;40:908-17.
36. Chiasson JL, Rabasa-Lhoret R. Prevention of type 2 diabetes: insulin resistance and beta-cell function. Diabetes 2004;53 Suppl 3:S34-8.
37. El Midaoui A, de Champlain J. Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid. Hypertension 2002;39:303-7.
38. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001;108:437-46.
39. Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004;6:280-5.
40. Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004;53:336-46.
41. Yang WS, Lee WJ, Huang KC, et al. mRNA levels of the insulin-signaling molecule SORBS1 in the adipose depots of nondiabetic women. Obes Res 2003;11:586-90.
42. Eldor R. Lipotoxicity versus adipotoxicity—The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes Diabetes Research and Clinical Practice 2006;74:S3-S8.
43. Yaturu S, Bridges JF, Subba Reddy DR. Decreased levels of plasma adiponectin in prediabetes, Type 2 diabetes and coronary artery disease. Med Sci Monit 2006;12:CR17-20.
44. Retnakaran R, Connelly PW, Maguire G, Sermer M, Zinman B, Hanley AJ. Decreased high-molecular-weight adiponectin in gestational diabetes: implications for the pathophysiology of Type 2 diabetes. Diabet Med 2007;24:245-52.
45. Altinova AE, Toruner F, Bozkurt N, et al. Circulating concentrations of adiponectin and tumor necrosis factor-alpha in gestational diabetes mellitus. Gynecol Endocrinol 2007;23:161-5.
46. Yang Y, Lu HL, Zhang J, et al. Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes. Int J Obes (Lond) 2006;30:439-46.
47. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815-9.
48. Yang WS, Lee WJ, Funahashi T, et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res 2002;10:1104-10.
49. Lu JY, Su TC, Liu YH, Hsu HJ, Chen CL, Yang WS. Lower plasma adiponectin is correlated to higher alanine aminotransferase independent of metabolic factors and hepatitis B virus carrier status. Intern Med J 2007;37:365-71.
50. Hickman IJ, Whitehead JP, Prins JB, Macdonald GA. Raised alanine transaminase and decreased adiponectin are features of the metabolic syndrome in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:438-40.
51. Liu CJ, Chen PJ, Jeng YM, et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005;43:235-42.
52. Lu JY, Chuang LM, Yang WS, et al. Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. Liver Int 2005;25:752-9.
53. Mojiminiyi OA, Abdella NA, Al Arouj M, Ben Nakhi A. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes. Int J Obes (Lond) 2007;31:213-20.
54. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-80.
55. Yang WS, Chuang LM. Human genetics of adiponectin in the metabolic syndrome. J Mol Med 2006;84:112-21.
56. Lin LY, Liau CS, Yang WS, Su TC. Decreased serum adiponectin in adolescents and young adults with familial primary hypercholesterolemia. Lipids 2005;40:163-7.
57. Yang WS, Hsiung CA, Ho LT, et al. Genetic epistasis of adiponectin and PPARgamma2 genotypes in modulation of insulin sensitivity: a family-based association study. Diabetologia 2003;46:977-83.
58. Yang WS, Tsou PL, Lee WJ, et al. Allele-specific differential expression of a common adiponectin gene polymorphism related to obesity. J Mol Med 2003;81:428-34.
59. Yang WS, Yang YC, Chen CL, et al. Adiponectin SNP276 is associated with obesity, the metabolic syndrome, and diabetes in the elderly. Am J Clin Nutr 2007;86:509-13.
60. Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes 2007;56:1198-209.
61. Tamura T, Yoneda M, Yamane K, et al. Serum leptin and adiponectin are positively associated with bone mineral density at the distal radius in patients with type 2 diabetes mellitus. Metabolism 2007;56:623-8.
62. Lautamaki R, Ronnemaa T, Huupponen R, et al. Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 2007;56:881-6.
63. Araki T, Emoto M, Yokoyama H, et al. The association of plasma adiponectin level with carotid arterial stiffness. Metabolism 2006;55:587-92.
64. Takagi T, Matsuda M, Abe M, et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2007.
65. Nomura S, Shouzu A, Omoto S, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res 2007.
66. Liu Y, Michael MD, Kash S, et al. Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes. Endocrinology 2007;148:683-92.
67. Yang WS, Chen MH, Lee WJ, et al. Adiponectin mRNA levels in the abdominal adipose depots of nondiabetic women. Int J Obes Relat Metab Disord 2003;27:896-900.
68. Oberbach A, Tonjes A, Kloting N, et al. Effect of a 4 week physical training program on plasma concentrations of inflammatory markers in patients with abnormal glucose tolerance. Eur J Endocrinol 2006;154:577-85.
69. Tsukinoki R, Morimoto K, Nakayama K. Association between lifestyle factors and plasma adiponectin levels in Japanese men. Lipids Health Dis 2005;4:27.
70. Adamia N, Virsaladze D, Charkviani N, Skhirtladze M, Khutsishvili M. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes. Georgian Med News 2007:52-5.
71. Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physical activities. Medicine and science in sports and exercise 1993;25:71-80.
72. Fields C, Dourson M, Borak J. Iodine-deficient vegetarians: A hypothetical perchlorate-susceptible population? Regulatory Toxicology and Pharmacology 2005;42:37-46.
73. Berkow SE, Barnard N. Vegetarian diets and weight status. Nutr Rev 2006;64:175-88.
74. Robinson F, Hackett AF, Billington D, Stratton G. Changing from a mixed to self-selected vegetarian diet--influence on blood lipids. J Hum Nutr Diet 2002;15:323-9.
75. Phillips F, Hackett AF, Stratton G, Billington D. Effect of changing to a self-selected vegetarian diet on anthropometric measurements in UK adults. J Hum Nutr Diet 2004;17:249-55.
76. Goff LM, Bell JD, So PW, Dornhorst A, Frost GS. Veganism and its relationship with insulin resistance and intramyocellular lipid. European journal of clinical nutrition 2005;59:291-8.
77. Sebekova K, Boor P, Valachovicova M, et al. Association of metabolic syndrome risk factors with selected markers of oxidative status and microinflammation in healthy omnivores and vegetarians. Molecular nutrition & food research 2006;50:858-68.
78. Colombo C, Muti P, Pala V, et al. Plant-based diet, serum fatty acid profile, and free radicals in postmenopausal women: the diet and androgens (DIANA) randomized trial. Int J Biol Markers 2005;20:169-76.
79. Davis BC, Kris-Etherton PM. Achieving optimal essential fatty acid status in vegetarians: current knowledge and practical implications. American Journal of Clinical Nutrition 2003;78:640S-6S.
80. Krajcovicova-Kudlackova M, Babinska K, Valachovicova M. Health benefits and risks of plant proteins. Bratisl Lek Listy 2005;106:231-4.
81. Famodu AA, Osilesi O, Makinde YO, Osonuga OA. Blood pressure and blood lipid levels among vegetarian, semi-vegetarian, and non-vegetarian vative Africans. Clinical Biochemistry 1998;31:545-9.
82. Burke LE, Styn MA, Steenkiste AR, Music E, Warziski M, Choo J. A randomized clinical trial testing treatment preference and two dietary options in behavioral weight management: preliminary results of the impact of diet at 6 months--PREFER study. Obesity (Silver Spring, Md 2006;14:2007-17.
83. Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term low-calorie low-protein vegan diet and endurance exercise are associated with low cardiometabolic risk. Rejuvenation research 2007;10:225-34.
84. Newby PK, Tucker KL, Wolk A. Risk of overweight and obesity among semivegetarian, lactovegetarian, and vegan women. Am J Clin Nutr 2005;81:1267-74.
85. Krajcovicova-Kudlackova M, Blazicek P. C-reactive protein and nutrition. Bratisl Lek Listy 2005;106:345-7.
86. Waldmann A, Koschizke JW, Leitzmann C, Hahn A. German vegan study: diet, life-style factors, and cardiovascular risk profile. Ann Nutr Metab 2005;49:366-72.
87. Hua NW, Stoohs RA, Facchini FS. Low iron status and enhanced insulin sensitivity in lacto-ovo vegetarians. The British journal of nutrition 2001;86:515-9.
88. Chang-Claude J, Frentzel-Beyme R, Eilber U. Mortality pattern of German vegetarians after 11 years of follow-up. Epidemiology 1992;3:395-401.
89. Hanf V, Gonder U. Nutrition and primary prevention of breast cancer: foods, nutrients and breast cancer risk. Eur J Obstet Gynecol Reprod Biol 2005;123:139-49.
90. Jenkins DJ, Kendall CW, Marchie A, et al. Type 2 diabetes and the vegetarian diet. The American journal of clinical nutrition 2003;78:610S-6S.
91. Bergesio F, Monzani G, Guasparini A, et al. Cardiovascular risk factors in severe chronic renal failure: the role of dietary treatment. Clin Nephrol 2005;64:103-12.
92. Famularo G, De Simone C, Pandey V, Sahu AR, Minisola G. Probiotic lactobacilli: an innovative tool to correct the malabsorption syndrome of vegetarians? Med Hypotheses 2005;65:1132-5.
93. Dunham L, Kollar LM. Vegetarian eating for children and adolescents. J Pediatr Health Care 2006;20:27-34.
94. Morad M, Gringols M, Kandel I, Merrick J. Vitamin B12 deficiency in persons with intellectual disability in a vegetarian residential care community. ScientificWorldJournal 2005;5:58-61.
95. Baatenburg de Jong A, Bekhof J, Zwart P, Langenhorst VJ, Roorda RJ. [Developmental delay in breastfed children due to inadequate diet of the mother]. Ned Tijdschr Geneeskd 2006;150:465-9.
96. Lin CL, Fang TC, Gueng MK. Vascular dilatory functions of ovo-lactovegetarians compared with omnivores. Atherosclerosis 2001;158:247-51.
97. Lu SC, Wu WH, Lee CA, Chou HF, Lee HR, Huang PC. LDL of Taiwanese vegetarians are less oxidizable than those of omnivores. J Nutr 2000;130:1591-6.
98. Chen CW, Lin YL, Lin TK, Lin CT, Chen BC, Lin CL. Total cardiovascular risk profile of Taiwanese vegetarians. European journal of clinical nutrition 2008;62:138-44.
99. Su TC, Jeng JS, Wang JD, et al. Homocysteine, circulating vascular cell adhesion molecule and carotid atherosclerosis in postmenopausal vegetarian women and omnivores. Atherosclerosis 2006;184:356-62.
100. Hung CJ, Huang PC, Li YH, Lu SC, Ho LT, Chou HF. Taiwanese vegetarians have higher insulin sensitivity than omnivores. The British journal of nutrition 2006;95:129-35.
101. Kuo CS, Lai NS, Ho LT, Lin CL. Insulin sensitivity in Chinese ovo-lactovegetarians compared with omnivores. European journal of clinical nutrition 2004;58:312-6.
102. Chen YC, Chiang CI, Lin RS, Pu YS, Lai MK, Sung FC. Diet, vegetarian food and prostate carcinoma among men in Taiwan. Br J Cancer 2005;93:1057-61.
103. Barnard ND, Scialli AR, Turner-McGrievy G, Lanou AJ, Glass J. The effects of a low-fat, plant-based dietary intervention on body weight, metabolism, and insulin sensitivity. The American journal of medicine 2005;118:991-7.
104. Wen CP, David Cheng TY, Tsai SP, et al. Are Asians at greater mortality risks for being overweight than Caucasians? Redefining obesity for Asians. Public health nutrition 2008:1-10.
105. Zhao W, Zhai Y, Hu J, et al. Economic burden of obesity-related chronic diseases in Mainland China. Obes Rev 2008;9 Suppl 1:62-7.
106. Yang Z, Hall AG. The financial burden of overweight and obesity among elderly Americans: the dynamics of weight, longevity, and health care cost. Health services research 2008;43:849-68.
107. Yurgin N, Secnik K, Lage MJ. Obesity and the use of insulin: a study of patients with type 2 diabetes in the UK. Journal of diabetes and its complications 2008;22:235-40.
108. Zahorska-Markiewicz B, Podolec P, Kopec G, et al. Polish Forum for Prevention Guidelines on overweight and obesity. Kardiologia polska 2008;66:594-6.
109. Zarocostas J. More health resources needed to curtail obesity epidemic in Europe. BMJ (Clinical research ed 2008;336:1155.
110. Yphantides N. For parents. Community solutions to childhood obesity. Diabetes self-management 2008;25:60, 2-4.
111. Yates SW. Obesity: where's the beef? Southern medical journal 2008;101:349-50.
112. Yannakoulia M, Panagiotakos D, Pitsavos C, et al. Five-year incidence of obesity and its determinants: the ATTICA Study. Public health nutrition 2008:1-8.
113. Wildman RP, Gu D, Muntner P, et al. Trends in overweight and obesity in Chinese adults: between 1991 and 1999-2000. Obesity (Silver Spring, Md 2008;16:1448-53.
114. White C. Government's obesity strategy targets parents of children under 10. BMJ (Clinical research ed 2008;337:a766.
115. Zaborskis A, Petronyte G, Sumskas L, Kuzman M, Iannotti RJ. Body image and weight control among adolescents in Lithuania, Croatia, and the United States in the context of global obesity. Croatian medical journal 2008;49:233-42.
116. Yuasa K, Sei M, Takeda E, et al. Effects of lifestyle habits and eating meals together with the family on the prevalence of obesity among school children in Tokushima, Japan: a cross-sectional questionnaire-based survey. J Med Invest 2008;55:71-7.
117. Wells JC, Hallal PC, Reichert FF, Menezes AM, Araujo CL, Victora CG. Sleep patterns and television viewing in relation to obesity and blood pressure: evidence from an adolescent Brazilian birth cohort. International journal of obesity (2005) 2008;32:1042-9.
118. Xanthakos SA. Bariatric surgery for extreme adolescent obesity: Indications, outcomes, and physiologic effects on the gut-brain axis. Pathophysiology 2008;15:135-46.
119. Wolnerhanssen BK, Peters T, Kern B, et al. Predictors of outcome in treatment of morbid obesity by laparoscopic adjustable gastric banding: results of a prospective study of 380 patients. Surg Obes Relat Dis 2008;4:500-6.
120. Wong PC, Chia MY, Tsou IY, et al. Effects of a 12-week exercise training programme on aerobic fitness, body composition, blood lipids and C-reactive protein in adolescents with obesity. Annals of the Academy of Medicine, Singapore 2008;37:286-93.
121. Grant R, Bilgin A, Zeuschner C, et al. The relative impact of a vegetable-rich diet on key markers of health in a cohort of Australian adolescents. Asia Pacific journal of clinical nutrition 2008;17:107-15.
122. Zhao D, Wang SR, Ma WW, Liu LJ, Sun CH. Alpha1-macroglobulin: a potential obesity-related factor in serum. Med Sci Monit 2008;14:BR57-61.
123. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008;57:1246-53.
124. Zannolli R, Mohn A, Buoni S, et al. Telomere length and obesity. Acta Paediatr 2008;97:952-4.
125. Bao Y, Lu J, Wang C, et al. Optimal waist circumference cutoffs for abdominal obesity in Chinese. Atherosclerosis 2008.
126. Abolfotouh MA, Soliman LA, Mansour E, Farghaly M, El-Dawaiaty AA. Central obesity among adults in Egypt: prevalence and associated morbidity. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit 2008;14:57-68.
127. Blaha MJ, Gebretsadik T, Shintani A, Elasy TA. Waist circumference, not the metabolic syndrome, predicts glucose deterioration in type 2 diabetes. Obesity (Silver Spring, Md 2008;16:869-74.
128. Zhang C, Rexrode KM, van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation 2008;117:1658-67.
129. Winter Y, Rohrmann S, Linseisen J, et al. Contribution of Obesity and Abdominal Fat Mass to Risk of Stroke and Transient Ischemic Attacks. Stroke; a journal of cerebral circulation 2008.
130. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology 2008.
131. Adams LA, Knuiman MW, Divitini ML, Olynyk JK. Body mass index is a stronger predictor of alanine aminotransaminase levels than alcohol consumption. Journal of gastroenterology and hepatology 2008;23:1089-93.
132. Brathwaite N, Fraser HS, Modeste N, Broome H, King R. Obesity, diabetes, hypertension, and vegetarian status among Seventh-Day Adventists in Barbados: preliminary results. Ethnicity & disease 2003;13:34-9.
133. de Mello VD, Zelmanovitz T, Perassolo MS, Azevedo MJ, Gross JL. Withdrawal of red meat from the usual diet reduces albuminuria and improves serum fatty acid profile in type 2 diabetes patients with macroalbuminuria. Am J Clin Nutr 2006;83:1032-8.
134. Barnard ND, Cohen J, Jenkins DJ, et al. A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care 2006;29:1777-83.
135. Waslaski J, Boucher J. Beyond bean sprouts. Vegetarianism today. Vegetarian eating can help protect your heart and cut your risk of several diseases--and it's more flexible than you might think. Diabetes forecast 2005;58:50-2, 4.
136. Wang JL, Shaw NS, Yeh HY, Kao MD. Magnesium status and association with diabetes in the Taiwanese elderly. Asia Pacific journal of clinical nutrition 2005;14:263-9.
137. Myers VH, Champagne CM. Nutritional effects on blood pressure. Current opinion in lipidology 2007;18:20-4.
138. Berkow SE, Barnard ND. Blood pressure regulation and vegetarian diets. Nutrition reviews 2005;63:1-8.
139. Appleby PN, Davey GK, Key TJ. Hypertension and blood pressure among meat eaters, fish eaters, vegetarians and vegans in EPIC-Oxford. Public health nutrition 2002;5:645-54.
140. Kwok TC, Chan TY, Woo J. Relationship of urinary sodium/potassium excretion and calcium intake to blood pressure and prevalence of hypertension among older Chinese vegetarians. European journal of clinical nutrition 2003;57:299-304.
141. Teixeira Rde C, Molina Mdel C, Zandonade E, Mill JG. Cardiovascular risk in vegetarians and omnivores: a comparative study. Arquivos brasileiros de cardiologia 2007;89:237-44.
142. De Biase SG, Fernandes SF, Gianini RJ, Duarte JL. Vegetarian diet and cholesterol and triglycerides levels. Arquivos brasileiros de cardiologia 2007;88:35-9.
143. Toohey ML, Harris MA, DeWitt W, Foster G, Schmidt WD, Melby CL. Cardiovascular disease risk factors are lower in African-American vegans compared to lacto-ovo-vegetarians. Journal of the American College of Nutrition 1998;17:425-34.
144. Brown WV. Atlas of Heart Diseases; 1996.
145. Basciano H, Federico L, Adeli K. Fructose, insulin resistance, and metabolic dyslipidemia. Nutrition & metabolism 2005;2:5.
146. Burke LE, Hudson AG, Warziski MT, et al. Effects of a vegetarian diet and treatment preference on biochemical and dietary variables in overweight and obese adults: a randomized clinical trial. Am J Clin Nutr 2007;86:588-96.
147. Ades PA, Savage PD, Toth MJ, et al. The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease. International journal of obesity (2005) 2008;32:967-74.
148. Bianchi G, Rossi V, Muscari A, Magalotti D, Zoli M. Physical activity is negatively associated with the metabolic syndrome in the elderly. Qjm 2008.
149. Kannel WB, Vasan RS, Keyes MJ, Sullivan LM, Robins SJ. Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). The American journal of cardiology 2008;101:497-501.
150. Atzmon G, Pollin TI, Crandall J, et al. Adiponectin levels and genotype: a potential regulator of life span in humans. The journals of gerontology 2008;63:447-53.
151. Hong SC, Yoo SW, Cho GJ, et al. Correlation between estrogens and serum adipocytokines in premenopausal and postmenopausal women. Menopause (New York, NY 2007;14:835-40.
152. Aviv A, Valdes A, Gardner JP, Swaminathan R, Kimura M, Spector TD. Menopause modifies the association of leukocyte telomere length with insulin resistance and inflammation. J Clin Endocrinol Metab 2006;91:635-40.
153. Manco M, Nolfe G, Calvani M, et al. Menopause, insulin resistance, and risk factors for cardiovascular disease. Menopause 2006;13:809-17.
154. Goodrow GJ, L'Hommedieu GD, Gannon B, Sites CK. Predictors of worsening insulin sensitivity in postmenopausal women. American journal of obstetrics and gynecology 2006;194:355-61.
155. Sites CK, L'Hommedieu GD, Toth MJ, Brochu M, Cooper BC, Fairhurst PA. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trial. The Journal of clinical endocrinology and metabolism 2005;90:2701-7.
156. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes, obesity & metabolism 2006;8:538-54.
157. Squillace N, Lapadula G, Torti C, et al. Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: a cross-sectional study. HIV medicine 2008;9:151-9.
158. Hsu CS, Liu CJ, Liu CH, et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008;28:271-7.
159. Neuschwander-Tetri BA. Hepatitis C virus-induced insulin resistance: not all genotypes are the same. Gastroenterology 2008;134:619-22.
160. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. Journal of hepatology 2008;48:28-34.
161.Wang CC, Hsu CS, Liu CJ, Kao JH, Chen DS. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. Journal of gastroenterology and hepatology 2008;23:779-82.
162.Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. The American journal of clinical nutrition 1982;36:936-42.
163.Sallis JF, Haskell WL, Wood PD, et al. Physical activity assessment methodology in the Five-City Project. American journal of epidemiology 1985;121:91-106.
164.簡盟月, 吳英黛, 關永基, 簡辰霖. 中文版七日回憶活動量問卷之信度及其與疾病和功能容量的相關. 物理治療 2003;28:01-8.
165.Hawley JA. Exercise as a therapeutic intervention for the prevention and treatment of insulin resistance. Diabetes Metab Res Rev 2004;20:383-93.
166.Ivy JL. Role of exercise training in the prevention and treatment of insulin resistance and non-insulin-dependent diabetes mellitus. Sports Med 1997;24:321-36.
167.Shaibi GQ, Roberts CK, Goran MI. Exercise and insulin resistance in youth. Exerc Sport Sci Rev 2008;36:5-11.
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/41939-
dc.description.abstract世界上隨著經濟的發展,肥胖已成為一個世界性的警訊,新陳代謝症候群也盛行於各國家,新陳代謝症候群與心血管中風有著密切的關係。不同的飲食型態可能影響體內代謝發炎狀況,因此素食者可能有較低的代謝疾病及心血管疾病風險、較好的胰島素敏感性、較好的血管內皮功能。
胰島素抗性是指胰島素的生理作用有缺陷,臨床表現有血脂異常、高血壓、葡萄糖不耐、或第二型糖尿病、高尿酸血症或痛風等。脂肪細胞分泌多種荷爾蒙,很多基因可在脂肪細胞內表達,如瘦素(leptin)、脂締素(adiponectin),近來已將脂肪細胞視為一種內分泌器官。脂締素是脂肪細胞分泌的荷爾蒙,在過重的人身上可見較低的脂締素。脂締素是一個重要的新陳代謝症候群的指標。脂締素有增加胰島素敏感的作用及避免動脈粥狀變化的保護作用,可抑制單核球黏至內皮細胞及脂質的堆積,並且經由抑制腫瘤壞死因子α而有抗發炎作用,低的血中脂締素與內皮細胞功能不良、心血管疾病、糖尿病、高血壓有關。本研究嘗試著驗證著成人女性素食者與非素食者各項身體因子與血液中生化因子,尤其是胰島素抗性、脂締素、活動量的關聯性。
研究方法與進行步驟:為一橫斷式關聯性研究。
對象: 以大林慈濟醫院參與健康檢查的健康人,經解說後簽署同意書後進行,本研究經研究倫理委員會通過後進行:
(1)定義: 研究定義素食者為蛋奶素或全素且維持一年以上者,非素食者定義為不合乎本研究定義素食者。
(2)問卷表格,如附件包括背景資料、身高、血壓、運動習慣等。
(3)配合受檢過程經八小時禁食後,進行高級體檢並登錄檢查結果,另配合體檢抽血留下3cc血液檢體,依研究檢驗步驟方法冷凍待收集完成,統一進行本實驗欲研究之因子檢測胰島素、脂締素。
結果與討論:共收案素食組397位,非素食組400位,整體年齡平均為55.10歲,標準差為8.81歲,比較素食組56.47 ± 8.88歲與非素食組53.71 ± 8.56歲的年紀,素食者年紀稍大,平均數差為2.76歲(p < 0.001)。在身高、體重、身體質量指數方面,素食者皆比較小。腰圍比較,素食組72.90 ± 6.88公分平均比非素食者74.61 ± 7.83公分小1.71公分(p = 0.003)。空腹血糖比較上,發現素食組89.78 ± 15.94mg/dL平均比非素食組91.48 ± 16.20mg/dL小1.70mg/dL (p = 0.007)。在總膽固醇、高密度脂蛋白膽固醇、低密度脂蛋白膽固醇,素食組平均皆比非素食組小。三酸甘油酯比較,兩組(素食組108.18 ± 68.15 mg/dL,非素食組102.16 ± 59.22 mg/dL)無差異(p = 0.121)。以腹部肥胖(腰圍大於或等於80公分)變項,取年紀、收縮壓、空腹血糖、三酸甘油酯、停經與否、每天每公斤活動仟卡數、素食與否做多因子邏輯斯迴歸,素食對非素食為顯著因子,素食者有較低的腹部肥胖機會(勝算比估計值0.412,95%信賴區間為0.274-0.62,p < 0.0001)。以糖尿病為依變項,對年紀、收縮壓、身體質量指數、三酸甘油酯、高密度脂蛋白膽固醇、停經與否、活動量、及素食與否做多因子邏輯斯迴歸分析,發現素食是一個顯著因子,素食組對非素食組有較低的糖尿病機會(勝算比估計值0.473,95%信賴區間為0.233-0.962,p = 0.0389)。對新陳代謝症候群台灣標準為依變項,取年紀、停經與否、及素食、素食年數、睡眠時間、每天活動仟卡數做邏輯斯迴歸,可得素食對非素食為顯著因子,素食者有較低的風險(勝算比估計值0.368,95%信賴區間為0.191-0.708,p = 0.0028)。以胰島素抗性(HOMA-IR)當成依變項,取年紀、收縮壓、腰圍、高密度脂蛋白膽固醇、三酸甘油酯、停經與否、素食、每天活動仟卡數作多因子線性迴歸分析,結果發現素食組顯著比非素食組低(β = -0.3548,p = 0.001)。以脂締素為依變項做多因子線性迴歸分析,發現素食(p = 0.3801)不是顯著因子。使用運動當量換算出一週的總活動量,其關於胰島素抗性的關係,在調整年紀、收縮壓、腰圍、總膽固醇、三酸甘油酯、停經、素食情形下,仍與胰島素抗性呈顯著負相關(β = -0.144,p = 0.0086),運動可以改善胰島素抗性。進一步分析素食年數對於胰島素抗性的關係,發現在11年內有顯著降低胰島素抗性的效果。
結論:素食對於健康的影響是廣泛性的,除了有較低的血糖、血脂、較低的肥胖糖尿病發生機會,並且是胰島素抗性獨立顯著因子,素食者有較低的胰島素抗性,素食者對於脂締素的關係則是可能透過影響其他身體因子如減少腰圍發生機會等,而有較好的關聯性。總活動量是胰島素抗性的獨立影響因子,兩者呈負相關,而活動量與脂締素並未有直接顯著關係。進一步的研究,要考慮性別是否有不同的效益,及長期追蹤素食對於身體的影響。
zh_TW
dc.description.abstractObesity is a global warning sign after the development of world economics. High prevalence rate of metabolic syndrome has been noted in the most countries. The different lifestyle may influence the inflammatory status of the body. Vegetarians may have the lower risk of metabolic and cardiovascular diseases, better insulin sensitivity, improved endothelium cells function.
Insulin resistance is a physiological defect of insulin function. The clinical manifestation is associated with dyslipidemia, type 2 diabetes, hypertension, gout etc. The fat cells can secret several hormones and several genes can be expressed in the fat cells., such as leptin, adiponectin.
Adiponectin, an adipose-derived plasma protein, has been well established as an important biomarker for metabolic syndrome. Plasma concentration of adiponectin was found to be lower in overweight or obese subjects. Adiponectin is associated with inproved insulin sensitivity and has the function of atherosclerosis prevention, inhibits the adhesion of manocytes to the endothelium cells and the accumulation of lipids, and has the potential of anti-inflammation by the inhibition of α-tumor necrosis factor. Low adiponectin level is associated with the endothelium dysfunction, cardiovascular disease, diabetes and carotid artery atherosclerosis. The aim of this cross sectional study is aimed to explore the effect of vegetarian lifestyle, physical activity and clinical outcomes on concentration of plasma adiponectin, and insulin resistance among vegetarians and omnivores of the female adults in Taiwan.
Methods: Those healthy adults that take part of Health Physical Exam are our possible study group. Informed consent will be given before enrollment .This study was approved by the IRB of the Buddhist Dalin Tzu Chi General Hospital.
1. Definition of vegetarians: those who practiced ovo-lacto-vegetarian diet or vegan for more than one year.
2. Questionnaires are including the demographic data, which including 7-day physical activity and exercise.
3. Blood was collected for routine physical exam and the data will be recorded for analysis. Another 10cc blood will be collected for adiponectin and insulin assay after informed consent.
Results: Totally 397 female vegetarians (VEG) and 400 female non-vegetarians (non-VEG), with a mean age of 55.10 (S.D.: 8.81) years old, were enrolled in our study. The year of VEG are 10.23±7.22. The age of VEG was significantly older than the non-VEG by 2.76 years (p < 0.001). There were no significant difference between the VEG and non-VEG group among systolic blood pressure (p = 0.566), diastolic blood pressure (p = 0.747), heart rate (p = 0.6547), triglyceride (p = 0.121) and the prevalence of diabetes (p = 0.235) and hypertension (p = 0.747). The VEG has better metabolic parameters than the non-VEG among the variables of body height ( mean difference = -0.81cm, p = 0.039), body weight [ mean difference (VEG minus non-VEG) = -2.12kg, p < 0.001],BMI ( mean difference = -0.67kg/m^2, p = 0.015), waist circumference ( mean difference = -1.71cm, p = 0.003), glucose AC ( mean difference = -1.70mg/dL, p = 0.007), total cholesterol ( mean difference = -16.45 mg/dL, p <0.001), high density lipoprotein-cholesterol ( mean difference = -3.86 mg/dL, p < 0.001), low density lipoprotein-cholesterol ( mean difference = -12.83 mg/dL, p < 0.001). Using multivariate logistic regression, the VEG (vs. non-VEG) is an independent factor for central obesity (OR: 0.412, 95%CI: 0.274-0.62, p < 0.0001) for central obesity after adjusting for the variables of age , systolic blood pressure, glucose AC, triglyceride (TG), menopause statue, activity score. Using logistic regression analysis with an adjustment for age, systolice blood pressure, body mass index, triglyceride, high density lipoprotein-cholesterol (HDL-C), menopause status, activity score, the VEG (vs. non-VEG) has a lower probability of diabetes, with an odds ratio of 0.473, 95%CI: 0.233-0.962, p = 0.0389). Using logistic regression analysis with an adjustment for age, menopause status, years of vegetarian diet, sleep hours, activity score, the VEG (vs. non-VEG) has a lower probability of Taiwan modified metabolic syndrome, with an odds ratio of 0.368, 95% CI: 0.191-0.708, p = 0.0028. For the insulin resistance, multivariate linear regression analysis showed that VEG (vs. non-VEG, β = -0.3548, p = 0.001) were significant independent factors when controlling for the variables of age, systolic blood pressure, waist, HDL-C, TG, menopause status, and activity score. Using multivariate linear regression analysis for adiponectin, VEG (vs. non-VEG, p = 0.3801) was not a significant factor. Daily activity is negative associated with insulin resistance(β = -0.144,p = 0.0086)after adjusting age, systolic blood pressure, waist, total cholesterol, TG, menopause status, vegetarian status. Moreover, the effect of VEG was most contributed by the cases of years of vegetarian diet below 11 years.
In conclusion, vegetarian lifestyle is good for health. The vegetarians have lower glucose, total cholesterol, HDL-C, LDL-C, waist circumference, and lower probability of obesity and diabetes. The vegetarian is an independent significant factor of insulin resistance and has lower insulin resistance. The association between smaller waist circumference, and lower probability of diabetes with vegetarian lifestyle may result into higher adiponectin level. The physical activity is an independent risk factor for insulin resistance. The higher physical activity score, the lower insulin resistance. There is no direct association between physical activity score with adiponectin. Further prospective follow up studies are still necessary for more investigation about the gender effect and the long term impact of vegetarian lifestyle on the health.
en
dc.description.provenanceMade available in DSpace on 2021-06-15T00:38:22Z (GMT). No. of bitstreams: 1
ntu-97-P95421007-1.pdf: 2220738 bytes, checksum: 96b89619a29b6d2895b8363f1e6a7445 (MD5)
Previous issue date: 2008
en
dc.description.tableofcontents口試審定書---------------------------------------------------------------------------------------i
謝誌------------------------------------------------------------------------------------------------ii
目錄-----------------------------------------------------------------------------------------------iii
圖目錄---------------------------------------------------------------------------------------------v
表目錄--------------------------------------------------------------------------------------------vi
中文摘要---------------------------------------------------------------------------------------viii
英文摘要-----------------------------------------------------------------------------------------xi
第一章 緒言-------------------------------------------------------------------------------------1
第二章 文獻回顧-------------------------------------------------------------------------------3
第一節 肥胖及新陳代謝症候群-------------------------------------------------------3
第二節 血脂肪----------------------------------------------------------------------------5
第三節 胰島素抗性----------------------------------------------------------------------7
第四節 脂締素(adiponectin)-------------------------------------------------------10
第五節 代謝當量評估------------------------------------------------------------------12
第六節 飲食型態與疾病---------------------------------------------------------------14
第三章 實驗方法與進行步驟---------------------------------------------------------------20
第一節 研究方法------------------------------------------------------------------------20
第二節 脂締素檢測---------------------------------------------------------------------21
第三節 胰島素檢測---------------------------------------------------------------------24
第四節 停經定義------------------------------------------------------------------------25
第五節 統計方法------------------------------------------------------------------------26
第四章 結果------------------------------------------------------------------------------------28
第一節 描述性結果---------------------------------------------------------------------28
第二節 以素食年數為自變項做單因子分析---------------------------------------31
第三節 以胰島素抗性為依變項做單因子相關性分析---------------------------32
第四節 以脂締素為依變項做單因子相關性分析---------------------------------33
第五節 對共病症做多因子分析------------------------------------------------------33
第六節 對新陳代謝症候群做多因子邏輯斯迴歸分析---------------------------39
第七節 對胰島素抗性做多因子迴歸分析------------------------------------------40
第八節 對脂締素做多因子迴歸分析------------------------------------------------41
第九節 關於肝炎的影響---------------------------------------------------------------42
第十節 不平衡選擇的檢定------------------------------------------------------------42
第十一節 素食年數對於胰島素抗性的影響---------------------------------------43
第五章 討論------------------------------------------------------------------------------------45
第一節 有關新陳代謝症候群---------------------------------------------------------46
第二節 有關胰島素抗性---------------------------------------------------------------50
第三節 有關脂締素---------------------------------------------------------------------51
第四節 有關停經、B、C型肝炎----------------------------------------------------52
第五節 運動當量------------------------------------------------------------------------54
第六節 結論------------------------------------------------------------------------------55
第六章 展望------------------------------------------------------------------------------------57
參考文獻----------------------------------------------------------------------------------------58
附錄一、問卷----------------------------------------------------------------------------------116
附錄二、研究倫理委員會同意書----------------------------------------------------------119
圖 目 錄
圖一、素食年數與人數分布圖---------------------------------------------------------------70
圖二、以尿酸對素食年數做散佈圖及迴歸線---------------------------------------------71
圖三、以高密度脂蛋白膽固醇對素食年數做散佈圖及迴歸線------------------------72
圖四、以低密度脂蛋白膽固醇對素食年數做散佈圖及迴歸線------------------------73
圖五、以胰島素抗性對(低密度脂蛋白膽固醇/高密度脂蛋白膽固醇比)做散佈圖及迴歸線-------------------------------------------------------------------------74
圖六、以胰島素抗性對(三酸甘油酯/高密度脂蛋白膽固醇比)做散佈圖及迴歸線----------------------------------------------------------------------------------------75
圖七、以胰島素抗性對脂締素(adioponectin)做散佈圖及迴歸線-------------------76
圖八、以脂締素對年紀做散佈圖及迴歸線-----------------------------------------------77
圖九、以脂締素對血色素做散佈圖及迴歸線--------------------------------------------78
圖十、以複廣義相加模式分析素食年數對胰島素抗性的影響效果之loess平滑成分圖-------------------------------------------------------------------------------------------79
表 目 錄
表一、現有文獻關於素食與非素食者的研究結果-------------------------------------80
表二、全部女性基本資料與不同飲食習慣基本資料比較表--------------------------82
表三、以素食年數對做單因子相關性檢定-----------------------------------------------85
表四、以胰島素抗性為依變項做單因子相關性分析-----------------------------------87
表五、對脂締素做單因子相關性分析-----------------------------------------------------89
表六、以身體質量指數為依變項作多因子線性迴歸分析----------------------------91
表七、以肥胖(BM≧I25)為依變項做多因子邏輯斯迴歸分析--------------------92
表八、以腰圍為依變項作多因子線性迴歸分析-----------------------------------------93
表九、以腹部肥胖為依變項做多因子邏輯斯迴歸分析--------------------------------94
表十、以腹部肥胖(腰圍大於80公分)為依變項做逐步邏輯斯迴歸-------------95
表十一、以空腹血糖為依變項做多因子線性迴歸--------------------------------------96
表十二、以糖尿病為依變項做邏輯斯迴歸分析------------------------------------------97
表十三、以收縮壓為依變項做多因子線性迴歸-----------------------------------------98
表十四、以高血壓為依變項做邏輯斯迴歸分析-----------------------------------------99
表十五、以三酸甘油酯為依變項做線性迴歸分析-------------------------------------100
表十六、以三酸甘油酯為依變項做線性迴歸分析-------------------------------------101
表十七、以高三酸甘油酯(≧150mg/dL)為依變項做邏輯斯迴歸分析--------102
表十八、以低密度脂蛋白膽固醇為依變項做線性迴歸分析------------------------103
表十九、以異常低密度脂蛋白膽固醇為依變項做邏輯斯迴歸分析-----------104
表二十、以高密度脂蛋白膽固醇為依變項做線性迴歸分析-------------------------105
表二十一、以異常高密度脂蛋白膽固醇為依變項做邏輯斯迴歸分析---------106
表二十二、對新陳代謝症候群台灣標準做多因子邏輯斯迴歸分析----------------107
表二十三、對國際糖尿病聯盟新陳代謝症候群標準做多因子邏輯斯迴歸分析-108
表二十四、以胰島素抗性為依變項做多因子線性迴歸結果-------------------------109
表二十五、以高胰島素抗性為依變項做多因子邏輯斯迴歸結果------------------110
表二十六、以脂締素為依變項做多因子線性迴歸分析結果------------------------111
表二十七、以脂締素25百分位為依變項做邏輯斯迴歸分析(一)--------------112
表二十八、以脂締素25百分位為依變項做邏輯斯迴歸分析(二)--------------113
表二十九、以高胰島素抗性為基礎做不平衡選擇檢定-------------------------------114
表三十、以胰島素抗性為依變項將素食年數分組後做多因子迴歸分析----------115
附表一、美國國立心肺血液研究所代謝當量編碼系統主要活動分類------------121
附表二、常見活動的代謝當量簡易分類表----------------------------------------------122
附表三、縮寫中英文對照表----------------------------------------------------------------123
dc.language.isozh-TW
dc.title台灣成人女性素食與非素食生活型態與各項身體因素及血液中生化因素的關係zh_TW
dc.titleThe Relationship between Vegetarian Lifestyle and Anthropometric and Biochemical Factors in Taiwanese Adult Femalesen
dc.typeThesis
dc.date.schoolyear97-1
dc.description.degree碩士
dc.contributor.oralexamcommittee黃瑞仁,陳祁玲,黃國晉
dc.subject.keyword素食,胰島素抗性,脂締素,新陳代謝症候群,代謝當量,zh_TW
dc.subject.keywordvegetarian,insulin resistance,adiponectin,metabolic syndrome,MET,en
dc.relation.page124
dc.rights.note有償授權
dc.date.accepted2008-11-06
dc.contributor.author-college醫學院zh_TW
dc.contributor.author-dept臨床醫學研究所zh_TW
顯示於系所單位:臨床醫學研究所

文件中的檔案:
檔案 大小格式 
ntu-97-1.pdf
  目前未授權公開取用
2.17 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved